Medtronic’s 2026 highlights: State Street’s 5% stake triggers mandatory disclosure, while LINQ monitors are pioneering cardiac studies in bears, elephants, and anteaters—offering new insights for veterinary and human heart care.
Medtronic’s dual‑front strategy uses LINQ cardiac monitors in wildlife research and partners with Hong Kong’s Cornerstone Robotics to bring its Sentire surgical system to new markets.
Medtronic’s Q2 2027 outlook: rising revenue, stronger margins, and breakthrough SPYRAL AFFIRM data, plus new FDA labeling and Parkinson’s partnership driving growth.